<DOC>
	<DOCNO>NCT02171507</DOCNO>
	<brief_summary>To investigate relative bioavailability dabigatran without concomitant administration diclofenac relative bioavailability diclofenac without concomitant administration dabigatran etexilate</brief_summary>
	<brief_title>Relative Bioavailability Dabigatran Diclofenac After Dabigatran Etexilate Diclofenac Single Dose Alone Following Concomitant Multiple Oral Administrations Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram , clinical laboratory test 2 . Age ≥18 ≤55 year 3 . Body mass index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 4 . Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Exclusion criterion : 1 . Clinically relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Relevant surgery gastrointestinal tract 3 . History bleed disorder include history gastrointestinal erosion ulcer acute blood coagulation defect 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History allergy/hypersensitivity ( include drug allergy ) deem relevant objective trial judge investigator 8 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 10 . Participation another trial investigational drug within two month prior administration trial 11 . Alcohol abuse ( 60 g/day ) 12 . Drug abuse 13 . Blood donation ( 100 mL within four week prior administration trial ) 14 . Excessive physical activity ( within one week prior administration trial ) 15 . Any laboratory value outside reference range clinical relevance 16 . Subjects abnormal thrombocyte count relevant deviation assessment platelet function ( PFA test ) must exclude 17 . Inability comply dietary regimen study centre 18 . Females child bear potential pregnant , breast feeding either surgically sterile sexually active use acceptable form contraception either oral contraceptive since least two month double barrier method , i.e . intrauterine device spermicide condom male partner 19 . Male subject must agree minimize risk female partner become pregnant first dose day 3 month completion post study medical examination . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month ) 20 . Planned surgery within four week follow endof study examination 21 . Intake medication , influence blood clotting , i.e. , acetylsalicylic acid , cumarin etc . 22 . The subject able understand comply protocol requirement , instruction protocolstated restriction 23 . Vulnerable subject ( e.g . person keep detention ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>